When it comes to dealing with chronic spontaneous urticaria (CSU), many patients find themselves at the end of their rope—especially when antihistamines just don’t cut it. It’s like trying to fix a leaky roof with a Band-Aid.
Enter the new hero: epinephrine nasal spray, specifically ARS-2 and Neffy. These aren’t your grandma’s allergy meds. They promise a shot—well, a spray—at relief when everything else fails.
The new heroes of allergy relief are here: ARS-2 and Neffy nasal sprays promise fast action when antihistamines let you down.
In a Phase 2 study involving 21 adults suffering from those pesky antihistamine-refractory CSU flare-ups, ARS-2 showed some serious potential. Patients received either a 1 mg or 2 mg dose, or a placebo. The results? Those treated with ARS-2 were more likely to be deemed “effectively treated” by investigators. Talk about a win! Minor side effects popped up, but hey, you can’t have it all, right? Satisfaction scores soared, leaving patients feeling like they actually mattered.
Then there’s Neffy. This nasal spray also stepped up to the plate and knocked it out of the park. Improvements in pruritus and hives were noted as quickly as five minutes after dosing. Yes, five minutes. That’s faster than waiting for your coffee to brew! In fact, Neffy demonstrated significant improvement in pruritus, hives, body surface area, and erythema during clinical trials. The upcoming regulatory approval for Neffy is expected later in 2024, further solidifying its role in treating these conditions.
The 1 mg dose was enough to stop mast cell degranulation, which is a fancy way of saying it helped calm things down. And the kicker? Both doses showed statistically significant reductions in itch and hives compared to placebo.
Let’s not forget the safety profile. Minor adverse events were the worst of it, which is a relief considering the alternative. Plus, this needle-free option would make anyone with a fear of needles breathe a little easier.
